Low immunoglobulin levels affect nearly 1 in 4 newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) and significantly increase infection risk during treatment. Patients with low ...

Patients aged 80+ with DLBCL show lower survival rates and higher treatment failure compared to younger groups. Older patients often have less education, live in more deprived areas, and ...

in a bit more depth as an example of other things that can be done with IHC. FL is the second most common subtype of ...

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings ...

Constitutive activation of the nuclear factor (NF)–κB pathway is essential for the survival of the least curable type of diffuse large B-cell lymphoma (DLBCL ...

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an aggressive form of non ...

BCL6 knock-out in a DLBCL xenograft induces tumor stasis ... (D) Tumor BCL6 protein levels were determined using IHC analysis. Representative images of BCL6 IHC staining in SU-DHL-4 tumors ...